Quanterix appoints Karen A. Flynn to Board of Directors effective June 6, 2022

Quanterix Corp

Appointed Karen A. Flynn as Class I director, term through 2024 annual meeting.
Initial equity award valued at $400,000: 60% stock options, 40% RSUs, vesting over three years.
Flynn is SVP and Chief Commercial Officer of Catalent Pharma Solutions (NYSE: CTLT).
No family relationships or arrangements with other directors/officers disclosed.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Karen A. Flynn

Class I Director

QTRX · Quanterix Corp

Effective: 2022-06-06
Filed: June 6, 2022, 7:59 PM ET

On June 3, 2022, the board of directors (the “Board”) of Quanterix Corporation (the “Company”) appointed Karen A. Flynn to serve on the Board, effective as of June 6, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Karen A. Flynn was appointed as Class I Director at Quanterix Corp.

Action: appointed
Role: Class I Director

Exact text from the filing

On June 3, 2022, the board of directors (the “Board”) of Quanterix Corporation (the “Company”) appointed Karen A. Flynn to serve on the Board, effective as of June 6, 2022.

View on SEC.gov

Quanterix Corp filing history →

Source: SEC EDGAR

accession 0001104659-22-068334

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.